AGP Picks
View all

News Channel Asia
Provided by AGP

News Channel Asia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on News Channel Asia.

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

Press releases published on June 8, 2026

METABORA GAMES Launches 'Puzzle & Guardians' as a LINE MINI App in Japan
Jun. 8, 2026

METABORA GAMES Launches 'Puzzle & Guardians' as a LINE MINI App in Japan

Indeterminate GlobeNewswire
Independent Proxy Advisory Firms ISS and Glass Lewis Unanimously Support the Election of ALL Director Nominees at Dynacor’s AGM
Jun. 8, 2026

Independent Proxy Advisory Firms ISS and Glass Lewis Unanimously Support the Election of ALL Director Nominees at Dynacor’s AGM

Indeterminate GlobeNewswire
Les cabinets indépendants de conseil en vote par procuration ISS et Glass Lewis appuient unanimement l’élection de TOUS les candidats au conseil d’administration lors de l’AGA de Dynacor
Jun. 8, 2026

Les cabinets indépendants de conseil en vote par procuration ISS et Glass Lewis appuient unanimement l’élection de TOUS les candidats au conseil d’administration lors de l’AGA de Dynacor

Indeterminate GlobeNewswire
DEEP SEA MINERALS CORP. PROVIDES STRATEGIC EXECUTION UPDATE
Jun. 8, 2026

DEEP SEA MINERALS CORP. PROVIDES STRATEGIC EXECUTION UPDATE

Indeterminate GlobeNewswire
CLIK CEO Purchases Shares Following Announcement of Strong Revenue Growth of 73% in Q3 FY2025/26
Jun. 8, 2026

CLIK CEO Purchases Shares Following Announcement of Strong Revenue Growth of 73% in Q3 FY2025/26

Indeterminate GlobeNewswire
CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
Jun. 8, 2026

CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

Indeterminate GlobeNewswire
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
Jun. 8, 2026

MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions

Indeterminate GlobeNewswire
Emerita Announces Appointment of New Independent Director
Jun. 8, 2026

Emerita Announces Appointment of New Independent Director

Indeterminate GlobeNewswire
Vema Hydrogen and First Atlantic Nickel & Cobalt Sign LOI to Develop Engineered Mineral Hydrogen at Pipestone XL Awaruite Project in Newfoundland
Jun. 8, 2026

Vema Hydrogen and First Atlantic Nickel & Cobalt Sign LOI to Develop Engineered Mineral Hydrogen at Pipestone XL Awaruite Project in Newfoundland

Indeterminate GlobeNewswire
Concorde International Group Enters Exclusive Partnership with TrackerHero, Onboarding Its Business Model–Driven, Technology-Enabled Facilities Security Operations
Jun. 8, 2026

Concorde International Group Enters Exclusive Partnership with TrackerHero, Onboarding Its Business Model–Driven, Technology-Enabled Facilities Security Operations

Indeterminate GlobeNewswire
Belo Sun Announces Management Transition
Jun. 8, 2026

Belo Sun Announces Management Transition

Indeterminate GlobeNewswire
EHang Announces US$30 Million Share Repurchase Program
Jun. 8, 2026

EHang Announces US$30 Million Share Repurchase Program

Indeterminate GlobeNewswire
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Jun. 8, 2026

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Indeterminate GlobeNewswire
SPARC AI Inc. Announces Closing of Final Tranche of Brokered LIFE Financing for $1.12 Million
Jun. 8, 2026

SPARC AI Inc. Announces Closing of Final Tranche of Brokered LIFE Financing for $1.12 Million

Indeterminate GlobeNewswire
A.I.S. Resources Announces Preliminary Rock Sample Assay Results at its New Brunswick Projects
Jun. 8, 2026

A.I.S. Resources Announces Preliminary Rock Sample Assay Results at its New Brunswick Projects

Indeterminate GlobeNewswire
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion 
Jun. 8, 2026

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion 

Indeterminate GlobeNewswire
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Jun. 8, 2026

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Indeterminate GlobeNewswire
Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement
Jun. 8, 2026

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Indeterminate GlobeNewswire
Enigmatig Limited Issues Statement on Recent Share Trading Activity
Jun. 8, 2026

Enigmatig Limited Issues Statement on Recent Share Trading Activity

Indeterminate GlobeNewswire
Heilongjiang's "Black Soil Premium Products" Brand Makes Debut at Guangzhou International Ecological Agricultural Products Expo
Jun. 8, 2026

Heilongjiang's "Black Soil Premium Products" Brand Makes Debut at Guangzhou International Ecological Agricultural Products Expo

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

News Channel Asia

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.